STRATA Skin Sciences, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Outubro 2023 - 5:02PM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (the “Company”), a
medical technology company dedicated to developing, commercializing
and marketing innovative products for the treatment of dermatologic
conditions, today announced that, as previously reported on its
Form 8-K filed on October 30, 2023, effective as of the close
of trading on October 31, 2023, the Company granted
equity-based awards, in accordance with Nasdaq Listing Rule
5635(c)(4), to Dr. Dolev Rafaeli as an inducement material to Dr.
Rafaeli entering into an employment agreement with the Company and
commencing employment as its Vice-Chairman, Chief Executive Officer
and President. Dr. Rafaeli received an equity-based award of a
stock option to purchase 1,754,569 shares of the Company’s
common stock, with a strike price of $0.53 per share, vesting over
a three-year period, with 145,465 options vesting on
January 31, 2024, and 145,464 options vesting every three
months thereafter, provided in general that Dr. Rafaeli remains in
the Company’s employ through each applicable vesting date and
subject to the terms and conditions of the applicable award
agreement.
About STRATA Skin Sciences,
Inc.STRATA Skin Sciences is a medical technology
company dedicated to developing, commercializing and marketing
innovative products for the in-office treatment of various
dermatologic conditions such as psoriasis, vitiligo, and acne. Its
products include the XTRAC® excimer laser, VTRAC® lamp
systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership
Program. STRATA’s popular partnership approach includes a fee per
treatment cost structure versus an equipment purchase, installation
and use of the device, on-site training for practice personnel,
service and maintenance of the equipment, dedicated account and
customer service associates, and co-op advertising support to help
raise awareness and promote the program within the practice.
Safe HarborThis press release
includes "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. These statements include
but are not limited to the Company’s plans, objectives,
expectations and intentions and may contain words such as “will,”
“may,” “seeks,” and “expects,” that suggest future events or
trends. These statements, the Company’s ability to launch and sell
an acne treatment device and to integrate that device into its
product offerings, the Company’s ability to develop, launch and
sell products recently acquired or to be developed in the future,
the Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from the
coronavirus, fiscal, and political factors, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the
Company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all these forward-looking
statements may prove to be incorrect or unreliable. The statements
in this press release are made as of the date of this press
release, even if subsequently made available by the Company on its
website or otherwise. The Company does not undertake any obligation
to update or revise these statements to reflect events or
circumstances occurring after the date of this press release. The
Company urges investors to carefully review
its SEC disclosures available
at www.sec.gov and www.strataskinsciences.com.
Investor Contact:Rich CockrellCG CapitalPhone:
+1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Strata Skin Sciences (NASDAQ:SSKN)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024